DOI: 10.1002/ajoc.201200130

Step-Economic and Protecting-Group-Free Total Synthesis of (+)-Cardiobutanolide

Rodney A. Fernandes* and Pullaiah Kattanguru^[a]



WILEY CONLINE LIBRARY

Abstract: A short protecting-groupfree synthesis of (+)-cardiobutanolide is reported. We have modified a onepot conversion of D-glucono- δ -lactone into the building block β -hydroxy- γ lactone. A series of cross-metathesis reactions and dihydroxylations either under the Sharpless conditions or achiral 4-methylmorpholine *N*-oxide (NMO) conditions were used to synthesize (+)-cardiobutanolide and its various diastereomers. In this endeavour, we have achieved a step-economic and protecting-group-free synthesis of (+)-cardiobutanolide in 22.4% overall yield from D-glucono- δ -lactone. A cross-metathesis reaction that is compatible with hydroxy groups and a substrate controlled Upjohn dihydroxylation reaction are key steps

in the synthesis. The synthesis is highly efficient and competitive with previous reports.

Keywords: asymmetric dihydroxylation • cardiobutanolide • crossmetathesis • natural products • styryllactones

quential double asymmetric dihydroxylation of a diene has been demonstrated by Chandrasekhar et al.^[6h] to achieve the synthesis of 1 over a lengthy linear sequence in 5%

overall yield. A recent synthesis by Pal and Shaw^[6i] used

a chiral building block approach starting from 3,4,6-tri-O-

benzyl-D-glucal and involved cross-metathesis and asym-

metric dihydroxylation as key steps (2% overall yield). A

review of literature syntheses indicates that most strategies

were designed with the use and/or replacement and remov-

al of one or multiple protecting groups. The syntheses were

dramatically lengthened by use of these protecting groups.

pecially skeleton-constructing reactions with tolerance for

various functional groups, protecting-group-free synthesis is

practical and in high demand.^[7] With our interest in design-

ing strategies for the total syntheses of natural products^[8]

we became interested in the development of a protecting-

group-free synthesis of 1 from the cheap and commercially

available material D-glucono-\delta-lactone. Our detailed retro-

synthetic approach towards developing a protecting-group-

free synthesis of 1 is outlined in Scheme 1. Our approach is

built on an interesting report by Song and Hollingsworth^[9]

about a one-pot conversion of D-glucono-ô-lactone 7 into

the key building block γ -lactone **3a**. We visualized a cross-

metathesis of 3a would lead to 5 or 2 depending on the

olefin partners 6 or 4, respectively. Asymmetric dihydroxy-

lation of 5 (with or without protecting groups) would lead

to 1. Similarly, asymmetric dihydroxylation and ketone re-

duction of 2 or the reverse sequence would also give 1. The

strategy holds potential for the syntheses of analogues of 1,

especially at the aryl end. Apart from the syntheses of ana-

logues, stereochemical variation could also be possible by

Results and Discussion

The synthesis commenced with the conversion of 7 into the

using enantiomers of 6 and/or 3a.^[9]

With the availability of many new synthetic methods, es-

Introduction

(+)-Cardiobutanolide (1), a styryllactone (Figure 1), was isolated from *Goniothalamus cardiopetalus* trees of the family *Annonaceae* in 2003 by Hisham et al.^[1] The plant family *Annonaceae* have yielded different types of natural

Figure 1. Structure of 1.

obutanolide is a target of synthetic interest. It contains a ylactone and polyhydroxy groups, which account for five contiguous stereocenters. Nearly a decade after it was first isolated, there have been nine reported syntheses of cardiobutanolide and/or its diastereomers.^[6] The first synthesis was reported by Murga and co-workers.^[6a] through an antiselective boronate aldol reaction of an L-erythrulose derivative in 9% overall yield. The synthesis by Yoda and Coworkers used D-glucuronolactone and involves a long synthetic route (9% overall yield).^[6b] A synthesis from D-glucose derivative was reported by Krishna et al.^[6c] in 8% overall yield. This was followed by a formal synthesis by Singh and co-workers^[6d] from a furanose derivative. Prasad et al.^[6e] developed a longer synthetic route from D-(-)-tartaric acid in 18% overall yield. The synthesis also involved inversion of configuration and multiple protecting groups. Krishna et al.^[6f] then reported a non-sugar-based synthesis of 1 through Sharpless kinetic resolution, cross-metathesis, and Sharpless asymmetric dihydroxylation (2% overall yield). Yadav et al.^[6g] developed a synthesis from the chiral pool material D-gluconolactone in 13% overall yield. A se-

 [a] Prof. R. A. Fernandes, P. Kattanguru Department of Chemistry Indian Institute of Technology Bombay Powai, Mumbai 400076, Maharashtra (India) Fax: (+91)22-25767152 E-mail: rfernand@chem.iitb.ac.in

Ided different types of natural products, such as acetogenins,^[2] isoquinoline alkaloids,^[3] and terpenoid compounds.^[4] Styryllactones are mainly isolated from the genus *Goniothalamus* and are known to have antitumor, teratogenic, pesticidal, cytotoxic, embryotoxic, and other biological activities.^[5] (+)-Cardi-

key building block γ -lactone **3a** or **3b**. The synthesis of **3a** from D-mannitol over a lengthy sequence of ten steps is

known.^[6f] Song and Hollingsworth^[9] reported a promising 58% yield (25 g scale reaction of **7**) in the one-pot conversion of **7** to **3a**. However, repetition of this reaction by Brimble and co-workers^[10] resulted in only a 7% yield after numerous attempts. Our efforts towards refinement of this

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/ajoc.201200130.



7 D-glucono-δ-lactone

Scheme 1. Retrosynthesis of **1**. TBDMS = *tert*-butyldimethylsilyl.

reaction are presented in Table 1. When the reported procedure^[9] was attempted, we encountered similar lower yields (Table 1, entry 1, 12%). The reaction was messy, involves froth formation and requires careful handling, espe-





cially while adding Zn dust. When the Zn dust treatment was carried out at 0°C initially and then the reaction heated to reflux, the yield improved to 24% of 3a (Table 1, entry 2). However, when the HBr treatment was shortened to 1 h at 50°C instead of overnight reaction,^[9] the yield improved to 45% (Table 1, entry 3). A combination of HBr treatment at 50°C for 1 h and Zn dust addition at -10°C over 1 h and then warming to room temperature over 2 h further improved the yield to 51% (Table 1, entry 4). This procedure was reproducible on less than four grams of 7. The β -hydroxy group of the crude product of the reaction in Table 1, entry 4 on protection with a silyl group gave 3b in 44% yield (Table 1, entry 5). When the reaction was washed with water and not treated with base, the γ -lactone 3c with an acetate group was obtained in 45% yield (Table 1, entry 6).

Further attempts to improve the yield were not successful. We could scale-up the reaction to 10 g of 7 (reactions conditions as in Table 1, entry 4) which gave **3a** in 48% yield. The lactones **3a** and **3b** were used in the cross-metathesis reaction with a suitable olefin partner **4**, **6a**, or **6b**. The results are shown in Table 2.

The cross-metathesis^[11] reaction of commercially available phenylvinyl ketone 4 with 3a did not occur with Grubbs second generation (G-II) catalyst (Table 2, entry 1). Compound 4 decomposed, whereas unreacted 3a was recovered. The reaction was achieved with the use of the Grubbs-Hoveyda^[11a, 12] catalyst (G-H-II) to give 2a in 48% yield (Table 2, entry 2). Similarly, the reaction of 4 with 3b also worked with the G-H-II catalyst to give 2b in 41% yield (Table 2, entry 4). The reaction of commercially available 6a and unprotected 3a also occurred with only the G-H-II catalyst (10 mol%) to provide 5a in 72% yield (Table 2, entry 6). In the reaction with G-II catalyst, 6a dimerized and **3a** was recovered^[13] (entry 5). The reaction of 6a with 3b occurred with the G-II and G-H-II catalysts in 72% and 63% yields, respectively, to give 5b (Table 2, entries 7 and 8). When 6b was treated with 3a in the presence of the G-II or G-H-II catalysts, 5c was obtained in low yields of 12% and 18%, respectively (Table 2, entries 9 and 10). The reaction of **6b** and **3b** with the hydroxy groups protected, failed with the G-II catalyst and resulted in recovery of the starting materials (Table 2, entry 11). However, the reaction worked with the G-H-II catalyst, albeit with lower yield of 28% of 5d (Table 2, entry 12). The lower yield could be attributed to the bulky silyl groups in the vicinity of the double bonds in both 3b and 6b, which results in steric crowding. The Grubbs first generation catalyst was ineffective for all of the above reactions.

With the skeletal structures **2a–b** and **5a–d** in hand, we moved to introduce the remaining hydroxy groups. The Sharpless asymmetric dihydroxylation^[14] (SAD) of **2a** gave a complex mixture with inseparable compounds (Scheme 2). We believe partial hemiacetal formation could lead to mixture of products. We planned to reduce the carbonyl group and then proceed with dihydroxylation. Towards this end, a (R)-(Me)-Corey-Bakshi-Shibata (CBS)

Table 2. Cross-metathesis of 3a/3b with 4, 6a or 6b.^[a]



[a] The G-I catalyst was ineffective in all cases. Unless otherwise mentioned, all reactions were carried out with catalyst ($5 \mod \%$) in anhydrous CH₂Cl₂ at reflux. [b] Whereas **4** decomposed, **3a** or **3b** were recovered. [c] Whereas **3a** was recovered, **6a** dimerized. [d] 10 mol % of G-H-II catalyst was used. [e] Starting materials recovered. NR = no reaction.

asymmetric reduction^[15] of 2a was executed. However, a conjugate addition occurred instead of ketone reduction to provide 8 in 92% yield. The chelation of the borane reagent with the free hydroxy group could be the reason for delivery of the hydride for conjugate addition. The SAD reaction of 2b gave 9a and 9b in a 1:3 diastereomeric ratio.^[16] These diastereoisomers could be efficiently separated to furnish 9a and 9b in 16 and 47% yields, respectively. When dihydroxylation was carried out without the (DHQD)₂-PHAL ligand and with NMO, the Upjohn process,^[17] 9a and 9b were formed in a 1:10 ratio^[16] (57% combined yield). Thus, the former SAD reaction on 2b was a mismatched case, in which strong substrate control is evident from the latter reaction without the use of a ligand.^[18] The ketone of 9a was subjected to reduction with NaBH₄ in the presence of CeCl₃·7H₂O to provide 10a in 90% yield. Similarly, the same reaction with 9b gave 10b in 91% yield. Other diastereomers were not isolated in this reduction reaction.^[19] Cleavage of the TBDMS group in 10a yielded 1 quantitatively ($[\alpha]_{D}^{25} = +7.6$ (c = 0.2, MeOH), lit.^[1] $[\alpha]_{D}^{24} = +6.4$ (c=0.28, MeOH)). The spectral and analytical data of 1 are identical to that reported in the literature.^[1,6a,e] Similarly, on removal of the TBDMS group, **10b** provided the diastereomer **11** quantitatively.

The SAD reaction of 5b gave a mixture of 9a and 9b in a 1:3 ratio after 12 h (Scheme 3). We isolated 9a and 9b in 21 and 65% yield respectively. The same reaction when carried out for a shorter time of 2 h gave keto-compound 2b in 65% yield.^[20] Thus, the oxidation of the benzylic hydroxy group occurred prior to dihydroxylation. The dihydroxylation reaction of 5b without the chiral ligand and using the Upjohn process^[17] gave **9a** and **9b** (51%) in a 1:7 ratio. In this case the benzylic alcohol oxidation also occurred. The reaction also confirmed a strong substrate control.^[18] We cross-checked the oxidation of the benzylic hydroxy group with the SAD reaction of (\pm) -6a. After a 12 h reaction we isolated a mixture of $(-)-12^{[21]}$ and 13 (mixture of diastereomers)^[22] in 37 and 36% yield, respectively (Scheme 3). The dihydroxylation reaction of 5c was not attempted because of lower yields in its preparation by crossmetathesis (Table 2, entries 9 and 10).

From the SAD reaction of 5d with the (DHQD)₂-PHAL ligand, we isolated three diastereomers 14a (31%), 14b (37%), and a minor unidentifiable diastereomer **14c** (7%). This reaction is reported in the literature by Krishna et al.^[6f] to give the two expected diastereomers in a 9:1 ratio. However, we noted discrepancies in the results we obtained in comparison with Krishna's report. The ¹H NMR spectral data of **14b** and **14c** matched exactly with the major and minor diastereomers reported by Krishna et al.^[6f] However, there was no description of 14a. Further elaboration of 14b by cleavage of the silvl ether groups yielded the diastereomer 15 in quantitative yield, the ¹H and ¹³C NMR spectra of which matched with the data reported by Krishna for 1.^[6f] As reported by Krishna et al., **1** has a signal at $\delta = 83.7$ ppm in the ¹³C NMR spectrum, which corresponds to C5, which we also detected at $\delta = 82.7$ ppm for 15. In the original report of its isolation, natural 1 has the same signal at 86.57 ppm. The earlier syntheses of 1 reported this peak as follows: Murga^[6a] (86.6 ppm), Prasad^[6e] (86.6 ppm), Yadav^[6g] (88.4 ppm), Chandrasekhar^[6h] (86.7 ppm), and Shaw^[6i] (86.6 ppm). Thus, a difference of approximately $\Delta \delta = 3.0$ ppm was detected for this peak in compound 15 relative to actual 1. On the contrary, we found that the diastereomer 14a quantitatively gave 1 after deprotection of the silvl groups. The signal at $\delta = 86.7$ ppm and all data exactly match the original isolation report as well other syntheses.^[1,6a,e,g,h,i]

Thus, we believe that Krishna et al.^[6f] did not isolate the chromatographically late-eluting diastereomer **14a** in the SAD reaction of **5d** (see the Experimental Section) but reported **14b** and **14c** with incorrect assignment of structure, and that **14b** gives **1**. As pure diastereomer **5d** cannot give three products in the SAD reaction, we consider **14c** to arise from the minor Z diastereomer of **5d** (which might be formed during the cross-metathesis reaction in a trace amount, though not detected in the NMR spectra) or by some other reaction. But we could not unambiguously



Scheme 2. SAD reaction of 2a and 2b and synthesis of 1.

assign the absolute structure for **14c**. We also observed a mismatch in the SAD reaction, wherein **14a** and **14b** were formed in a 1:1.2 ratio. The dihydroxylation reaction of **5d** without the chiral ligand but with NMO gave **14a** (15%) and **14b** (47%) in a 1:3 ratio, which confirms substrate control (Scheme 3).^[18]

For a practical, step-economic, and protecting-group-free synthesis of 1, we used 5a, as shown in Scheme 4. The SAD reaction of 5a under standard Sharpless conditions with the $(DHQD)_2$ -PHAL ligand for 12 h at 0°C gave a complex mixture of inseparable products. However, when the reaction time was reduced to 2 h we obtained the benzylic alcohol oxidation product 2a in 92% yield rather than dihydroxylation products. The dihydroxylation of 5a without the Sharpless conditions but with NMO gave a diastereomeric mixture (15/1, dr=1:4) from which we isolated 15 in 15% yield and 1 in 61% yield. We believe that the substrate control is more from the benzylic alcohol part than the lactone part in compound 5a, where 1 is the major product.

Conclusions

In conclusion we have demonstrated a reliable modification of one-pot conversion of D-glucono- δ -lactone into the β -hydroxy-y-lactone 3. Further, a series of cross-metathesis reactions were carried out to construct the olefins that are the skeletal structures of cardiobutanolide. These olefins were subjected to a dihydroxylation reaction either under Sharpless conditions or achiral NMO conditions. Some of the intermediates were efficiently converted into 1 and its various diastereomers. Finally, we have achieved a practical, step-economic, and protecting-group-free synthesis of $\mathbf{1}^{[23]}$ in 22.4% overall yield from D-glucono-δ-lactone. A crossmetathesis reaction between 3a and 6a that is compatible with hydroxy groups and a substrate-controlled dihydroxylation reaction are key steps in the synthesis. The synthesis is highly efficient and competitive with previous reports in literature.



Scheme 3. SAD reaction of 5b and 5d and synthesis of 1.

Experimental Section

General Information

Flasks were oven or flame dried and cooled in a desiccator. Anhydrous reactions were carried out under an atmosphere of Ar or N₂. Solvents and reagents were purified by standard methods. Zn powder was obtained from a local commercial source and was 325 mesh. Thin layer chromatography was performed on EM 250 Kieselgel 60 F254 silica gel plates. The spots were visualized by staining with KMnO₄ or by UV lamp. ¹H NMR and ¹³C NMR spectra were recorded at 400 and 100 MHz, respectively, and chemical shifts are based on the tetramethyl-silane signal at δ =0.00 pm for ¹H NMR spectra and the CDCl₃ signal at δ =77.00 ppm (t) or the [D₆]acetone signal at 29.80 ppm (septet) in ¹³C NMR spectra. IR samples were prepared by evaporation from

CHCl₃ on CsBr plates or as KBr pellets. High-resolution mass spectra were obtained in positive electrospray ionization mode.

(4R,5R)-4-Hydroxy-5-vinyldihydrofuran-2(3H)-one (3a)

Reaction conditions were as stated in Table 1, entry 4. Hydrogen bromide in acetic acid (HBA, 33%, 16 mL) was added to 7 (4.0 g, 22.45 mmol) and the reaction mixture stirred at 50 °C for 1 h. The mixture was then cooled to room temperature and excess HBA was removed under reduced pressure. The resultant syrupy liquid was dissolved in 50% aqueous acetic acid (40 mL), then cooled to -10 °C and zinc powder (8.07 g, 123.49 mmol, 5.5 equiv) was added in portions over 1 h at -10 °C. The mixture was stirred and warmed to room temperature over 2 h and then heated to 60 °C for an additional 1 h. The mixture was then filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in water (30 mL), cooled to 0 °C, and the pH ad-



Scheme 4. Protecting-group-free synthesis of 1.

justed to 10 by slow addition of KOH pellets to precipitate the remaining zinc as the insoluble hydroxide and to affect C3 deacetylation. After filtration, the basic filtrate was acidified to pH 5 with concentrated hydrochloric acid at 0°C. Water was removed under reduced pressure and the residue was dissolved in cold ethanol. Precipitated potassium chloride was removed by filtration and the filtrate was concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (1:1) as eluent to give **3a** (1.46 g, 51 %). $[\alpha]_{D}^{22}$ 45.3 (c=0.8, CHCl₃), lit.^[9] [α]_D = +43 (c=1.15, CHCl₃); IR (CHCl₃): $\tilde{\nu}_{\rm max} \!=\! 3447, \ 2934, \ 1771, \ 1639, \ 1432, \ 1413, \ 1333, \ 1309, \ 1203, \ 1158, \ 1080,$ 1017, 990, 962, 901, 884, 833, 796 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta =$ 6.01-5.92 (m, 1H), 5.59-5.49 (m, 2H), 4.94-4.91 (m, 1H), 4.56-4.53 (m, 1 H), 2.80 (dd, J = 17.7, 5.4 Hz, 1 H), 2.63 (dd, J = 17.7, 1.3 Hz, 1 H), 2.27 ppm (br s, 1 H, OH); 13 C NMR (100 MHz, CDCl₃): $\delta = 176.1$, 130.2, 120.6, 84.9, 69.4, 38.6 ppm; HRMS: m/z: calcd for [C₆H₈O₃+H]⁺: 129.0552; found: 129.0551.

(4R,5R)-4-tert-Butyldimethylsilyloxy-5-vinyldihydrofuran-2(3H)-one (3b)

By using similar procedure as above with 7, 4.0 g, the crude hydroxy lactone 3a (1.70 g, 13.27 mmol) obtained was dissolved in anhydrous CH₂Cl₂ (30 mL), then imidazole (1.80 g, 26.54 mmol, 2.0 equiv) and tertbutyldimethylsilyl chloride (2.99 g, 19.90 mmol, 1.5 equiv) were added at 0°C. The reaction mixture was stirred at room temperature for 12 h and then diluted with CH2Cl2 (10 mL), H2O (10 mL), and extracted with CH_2Cl_2 (3×20 mL). The combined organic phases were washed with water, brine, dried (Na₂SO₄) and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (9:1) as eluent to afford **3b** (2.38 g, 44%) as a colorless oil: $[\alpha]_D^{25} = +$ 15.9 (c = 1.0, CHCl₃); IR (CHCl₃): $\tilde{\nu}_{max} = 2956$, 2932, 2859, 1781, 1473, 1259, 1206, 1149, 1096, 1029, 946, 841, 779 $\rm cm^{-1}; \ ^1H \ NMR$ (400 MHz, CDCl₃): $\delta = 5.91-5.82$ (m, 1H), 5.33-5.25 (m, 2H), 4.67 (dd, J = 7.2, 4.2 Hz, 1 H), 4.40-4.37 (m, 1 H), 2.61 (dd, J=17.2, 5.4 Hz, 1 H), 2.37 (dd, J=17.2, 2.1 Hz, 1 H), 0.76 (s, 9 H), -0.05 (s, 3 H), -0.06 ppm (s, 3 H); $^{13}\mathrm{C}\,\mathrm{NMR}$ (100 MHz, CDCl₃): $\delta\!=\!175.2,\ 131.8,\ 119.9,\ 85.4,\ 70.7,\ 39.3,$ 25.6, 18.0, -4.9, -5.0 ppm; HRMS: m/z: calcd for $[C_{12}H_{22}O_3Si+H]^+$: 243.1415; found: 243.1418.

(4R,5R)-4-Acetyloxy-5-vinyldihydrofuran-2(3H)-one (3c)

Reaction conditions were as stated in Table 1, entry 6. HBA in acetic acid (33%, 16 mL) was added to **7** (4.0 g, 22.45 mmol) and the reaction mixture stirred at 50°C for 1 h. The mixture was then cooled to room temperature, excess HBA was removed under reduced pressure. The resultant syrupy liquid was dissolved in 50% aqueous acetic acid (40 mL), then cooled to -10° C and zinc powder (8.07 g, 123.49 mmol, 5.5 equiv) was added in portions over 1 h at -10° C. The mixture was warmed to

room temperature over 2 h and then heated to 60 °C for an additional 1 h. The mixture was then filtered and the filtrate was concentrated under reduced pressure. The residue was dissolved in water (30 mL) and extracted with CH₂Cl₂ (3×40 mL). The combined organic phases were washed with brine, dried (Na₂SO₄), and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (7:3) as eluent to give **3c** (1.72 g, 45%). $[a]_D^{25} = +29.6$ (c = 1.0, CHCl₃); IR (CHCl₃): $\bar{v}_{max} = 3091$, 2998, 2938, 1789, 1747, 1649, 1432, 1375, 1237, 1149, 1062, 990, 942, 903, 761, 708 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 5.88-5.80$ (m, 1H), 5.55–5.52 (m, 2H), 5.39 (dd, J = 10.7, 1.2 Hz, 1H), 5.03 (td, J = 4.9, 1.1 Hz, 1H), 2.91 (dd, J = 18.2, 6.3 Hz, 1H), 2.65 (dd, J = 18.2, 2.0 Hz, 1H), 2.08 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 173.7$, 169.8, 129.5, 120.5, 82.7, 70.8, 35.9, 20.7 ppm; HRMS: m/z: calcd for [C₈H₁₀O₄+H]⁺: 171.0657; found: 171.0652.

General Procedure for Cross-Metathesis Reactions

G-H-II, G-II, or G-I catalyst (5 mol%) was added to a stirred and degassed solution of **3a-b** (1 equiv) and **4** or **6a-b** (1.2–5.0 equiv) in anhydrous CH_2Cl_2 at room temperature and the mixture stirred at reflux for 48–144 h. The mixture was cooled to room temperature, filtered through a small pad of silica gel, and the filtrate concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc to give **2a-b** or **5a-d** (for yields see Table 2). The Z isomer was not formed within the detectable limit of the ¹H NMR spectra of the isolated products. The G-I catalyst was ineffective in cross-metathesis reaction in all cases.

(4R,5R)-4-Hydroxy-5-[(E)-3-oxo-3-phenylprop-1-en-1-yl]dihydrofuran-2(3H)-one (**2***a*)

The reaction of **3a** (50 mg, 0.39 mmol), **4** (260 mg, 1.95 mmol, 5.0 equiv), and the G-H-II catalyst (12.2 mg, 0.0195 mmol, 5 mol%) gave **2a** (43.6 mg, 48%) as a colorless solid: m.p. 148–150°C; $[a]_D^{25} = +39.3$ (*c*= 0.3, MeOH); IR (KBr): $\tilde{\nu}_{max} = 3407$, 1777, 1623, 1382, 1315, 1276, 1197, 1161, 1134, 1073, 975, 895, 775, 701 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.98$ (d, J = 7.3 Hz, 2H), 7.61 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.40 (dd, J = 15.4, 1.7 Hz, 1H), 7.04 (dd, J = 15.5, 4.1 Hz, 1H), 5.21 (td, J = 3.9, 1.8 Hz, 1H), 4.77 (ddd, J = 5.3, 3.9, 1.3 Hz, 1H), 2.88 (dd, J = 17.7, 5.5 Hz, 1H), 2.72 (dd, J = 17.6, 1.3 Hz, 1H), 1.79 ppm (br s, 1H, OH); ¹³C NMR (100 MHz, CDCl₃): $\delta = 189.9$, 174.7, 138.6, 136.7, 133.7, 128.9, 128.8, 127.6, 83.0, 69.4, 38.5 ppm; HRMS: *m/z*: calcd for [C₁₃H₁₂O₄+H]⁺: 233.0814; found: 233.0823.

(4R,5R)-4-tert-Butyldimethylsilyloxy-5-[(E)-3-oxo-3-phenylprop-1-en-1-yl]dihydrofuran-2(3H)-one (**2**b)

The reaction of **3b** (20 mg, 0.082 mmol), **4** (22 mg, 0.165 mmol, 2.0 equiv), and the G-H-II catalyst (2.6 mg, 0.004 mmol, 5 mol%) gave **2b** (11.7 mg, 41%) as a yellow solid: m.p. 74–76°C; $[a]_{25}^{25} = +35.1$ (*c*= 0.5, CHCl₃); IR (KBr): $\bar{\nu}_{max} = 2931$, 2858, 1770, 1674, 1629, 1270, 1203, 1158, 1098, 1038, 919, 835, 778, 711 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.99-7.96$ (m, 2H), 7.61–7.56 (m, 1H), 7.51–7.47 (m, 2H), 7.27 (dd, J = 15.5, 1.7 Hz, 1H), 6.98 (dd, J = 15.5, 4.5 Hz, 1H), 5.14 (td, J = 4.4, 1.7 Hz, 1H), 4.69–4.66 (m, 1H), 2.81 (dd, J = 17.3, 5.4 Hz, 1H), 2.54 (dd, J = 17.3, 2.1 Hz, 1H), 0.81 (s, 9H), 0.06 (s, 3H), 0.04 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 189.2, 174.6, 139.8, 137.1, 133.2, 128.7, 128.6, 126.9, 83.2, 70.3, 39.2, 25.6, 25.5, 17.9, -5.0, -5.1 ppm; HRMS:$ *m*/*z*: calcd for [C₁₉H₂₆O₄Si+H]⁺: 347.1679; found: 347.1673.

(4R,5R)-4-Hydroxy-5-[(S,E)-3-hydroxy-3-phenylprop-1-en-1-yl]dihydrofuran-2(3H)-one (5a)

The reaction of **3a** (130 mg, 1.01 mmol), (*S*)-phenylvinyl carbinol **6a** (204 mg, 1.52 mmol, 1.5 equiv), and the G-H-II catalyst (63.3 mg, 0.101 mmol, 10 mol%) gave **5a** (171 mg, 72%) as a colorless soild: m.p. 83–85°C; $[a]_{D}^{25} + 6.2$ (c=0.5, CHCl₃); IR (CHCl₃): $\dot{v}_{max} = 3425$, 2925, 2854, 1777, 1493, 1454, 1405, 1328, 1162, 1076, 1016, 970, 906, 761, 702 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\dot{\sigma} = 7.40-7.29$ (m, 5 H), 6.14 (ddd, J=15.7, 5.5, 1.1 Hz, 1H), 5.97 (ddd, J=15.7, 6.3, 1.3 Hz, 1H), 5.27 (d, J=5.4 Hz, 1H), 4.92 (dd, J=6.2, 3.7 Hz, 1H), 4.52 (t, J=4.2 Hz, 1H), 2.94 (br s, 1H, OH), 2.78 (dd, J=17.7, 5.4 Hz, 1H), 2.72 (br s, 1H, OH), 2.78 (dd, J=17.7, 5.4 Hz, 1H), 2.72 (br s, 1H, OH), 2.62 ppm (dd, J=17.7, 1.1 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): $\dot{\sigma} = 176.3$, 141.7, 137.8, 128.6, 127.9, 126.5, 126.4, 123.3, 84.4, 73.7, 69.8, 38.5 ppm; HRMS: m/z: calcd for $[C_{13}H_{14}O_4+Na]^+$: 257.0790; found: 257.0793.

(4R,5R)-4-(tert-Butyldimethylsilyloxy)-5-[(S,E)-3-hydroxy-3-phenylprop-1-en-1-yl]dihydrofuran-2(3H)-one (**5** b)

The reaction of **3b** (300 mg, 1.24 mmol), (*S*)-phenylvinylcarbinol **6a** (200 mg, 1.49 mmol, 1.2 equiv), and the G-II catalyst (52.6 mg, 0.062 mmol, 5 mol %) gave **5b** (310 mg, 72 %) as colorless solid: m.p. 99–101 °C; $[\alpha]_D^{25} = +8.8$ (c=0.4, CHCl₃); IR (CHCl₃): $\bar{\nu}_{max} = 3450$, 2955, 2930, 2858, 1784, 1464, 1259, 1215, 1161, 1096, 1025, 974, 954, 906, 840, 760, 701 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.37-7.27$ (m, 5H), 6.08 (ddd, J = 15.6, 5.4, 0.7 Hz, 1H), 5.94 (ddd, J = 15.6, 7.3, 1.3 Hz, 1H), 5.29 (d, J = 5.4 Hz, 1H), 4.83 (dd, J = 7.3, 4.0 Hz, 1H), 4.72 (dd, J = 17.2, 5.4 Hz, 1H), 2.50 (dd, J = 17.2, 1.9 Hz, 1H), 1.98 (br s, 1H, OH), 0.87 (s, 9H), 0.06 ppm (s, 6H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 175.3$, 142.0, 138.1, 128.5, 127.8, 126.3, 123.8, 84.7, 73.9, 70.6, 39.4, 25.5, 18.0, -4.96, -5.0 ppm; HRMS: m/z: calcd for [C₁₉H₂₈O₄Si+Na]⁺: 371.1655; found: 371.1662.

(4R,5R)-5-[(S,E)-3-(tert-Butyldimethylsilyloxy)-3-phenylprop-1-en-1yl]-4-hydroxydihydrofuran-2(3H)-one (5c)

The reaction of **3a** (20 mg, 0.156 mmol), **6b** (46 mg, 0.187 mmol, 1.2 equiv), and the G-H-II catalyst (4.9 mg, 0.0078 mmol, 5 mol%) gave **5c** (9.8 mg, 18%) as colorless oil. $[\alpha]_{D}^{25} = -20.1$ (c=0.2, CHCl₃); IR (CHCl₃): $\tilde{\nu}_{max} = 3465$, 2929, 2857, 1773, 1638, 1472, 1258, 1163, 1118, 1017, 907, 877, 838, 760, 701 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.38-7.26$ (m, 5H), 6.15 (ddd, J=15.5, 4.8, 1.1 Hz, 1H), 5.91 (ddd, J=15.5, 6.3, 1.5 Hz, 1H), 5.32 (d, J=4.8 Hz, 1H), 4.94–4.92 (m, 1H), 4.50 (td, J=4.5, 1.1 Hz, 1H), 2.78 (dd, J=17.6, 5.4 Hz, 1H), 2.63 (dd, J=17.6, 1.2 Hz, 1H), 1.98 (br s, 1H, OH), 0.94 (s, 9H), 0.10 (s, 3H), -0.01 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 175.1$, 142.7, 140.5, 128.4, 127.5, 125.9, 120.1, 83.7, 74.3, 69.6, 38.6, 25.8, 18.3, -4.8, -4.9 ppm; HRMS: m/z: calcd for [C₁₉H₂₈O₄Si+Na]⁺: 371.1655; found: 371.1664.

(4R,5R)-4-(tert-Butyldimethylsilyloxy)-5-[(S,E)-3-(tertbutyldimethylsilyloxy)-3-phenylprop-1-en-1-yl]dihydrofuran-2(3H)-one (5d)

The reaction of **3b** (30 mg, 0.124 mmol), **6b** (46 mg, 0.185 mmol, 1.5 equiv), and the G-H-II catalyst (3.9 mg, 0.0062 mmol, 5 mol%) gave

5d (16 mg, 28%) as colorless oil. $[a]_D^{25} = -44.1$ (c=0.4, CHCl₃); IR (CHCl₃): $\vec{v}_{max} = 3028$, 2956, 2930, 2887, 2858, 1790, 1464, 1472, 1362, 1258, 1204, 1159, 1121, 1026, 973, 952, 905, 880, 838, 776, 758, 700 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.31-7.22$ (m, 5H), 5.97–5.96 (m, 2H), 5.25 (d, J=2.5 Hz, 1H), 4.75 (dd, J=7.1, 3.9 Hz, 1H), 4.43–4.40 (m, 1H), 2.71 (dd, J=17.2, 5.2 Hz, 1H), 2.46 (dd, J=17.2, 1.7 Hz, 1H), 0.90 (s, 9H), 0.89 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H), 0.03 (s, 3H), -0.06 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 175.3$, 143.0, 140.3, 128.2, 127.2, 126.0, 121.1, 85.2, 74.3, 70.8, 39.5, 25.8, 25.7, 18.2, 18.0, -4.9, -4.94, -5.0 ppm; HRMS: m/z: calcd for $[C_{25}H_{42}O_4Si_2+Na]^+$: 485.2519; found: 485.2511.

(4R,5R)-4-Hydroxy-5-(3-oxo-3-phenylpropyl)dihydrofuran-2(3H)-one (8):

BH₃·Me₂S (0.05 mL, 0.516 mmol, 1.2 equiv) was added to a stirred solution of (R)-2-methyl-CBS-oxazaborolidine (1.0 M solution in toluene, 0.52 mL, 0.52 mmol, 1.2 equiv) in anhydrous THF (15 mL) at 0°C. After stirring for 30 min, the solution was cooled to -20 °C and a solution of 2a (100 mg, 0.43 mmol) in anhydrous THF (5 mL) was added dropwise over 10 min. The reaction mixture was warmed to 0 °C over 1 h and then quenched with MeOH (1 mL). The solution was stirred for 15 min at room temperature and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (1:1) as eluent to afford 8 (92.8 mg, 92%) as colorless solid: m.p. 121-123°C; $[\alpha]_{D}^{25} = +52.9$ (c=0.75, CHCl₃); IR (CHCl₃): $\tilde{\nu}_{max} = 3398$, 2929, 2857, 1770, 1679, 1598, 1449, 1407, 1203, 1161, 1079, 1025, 982, 883, 756, 691 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.97$ (d, J = 8.1 Hz, 2H), 7.61–7.58 (m, 1H), 7.50–7.46 (m, 2H), 4.47–4.39 (m, 2H), 3.32 (dt, J =18.5, 6.0 Hz, 1 H), 3.25–3.16 (m, 1 H), 2.78 (dd, J=17.7, 5.4 Hz, 1 H), 2.60 (d, J=17.6 Hz, 1H), 2.40–2.31 (m, 1H), 2.27–2.17 ppm (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 200.2, 175.8, 136.2, 133.7, 128.7, 128.1, 84.5, 68.6, 39.0, 34.4, 22.0 ppm; HRMS: *m/z*: calcd for [C₁₃H₁₄O₄+H]⁺: 235.0970; found: 235.0979.

(4R,5R)-4-(tert-Butyldimethylsilyloxy)-5-[(1S,2S)-1,2-dihydroxy-3-oxo-3-phenylpropyl]dihydrofuran-2(3H)-one (**9***a*) and (4R,5R)-4-(tert-butyldimethylsilyloxy)-5-[(1R,2R)-1,2-dihydroxy-3-oxo-3-phenylpropyl]dihydrofuran-2(3H)-one (**9***b*)

 $K_2OsO_4{\boldsymbol{\cdot}}2H_2O~(0.53~\text{mg},\,0.00145~\text{mmol},\,0.5~\text{mol}\,\%)$ was added to a mixture of K₃Fe(CN)₆ (334 mg, 1.015 mmol, 3.5 equiv), K₂CO₃ (140 mg, 1.015 mmol, 3.5 equiv) and (DHQD)₂PHAL (2.5 mg, 0.0032 mmol, 1.1 mol%) in tBuOH-H2O (1:1, 4 mL) cooled at 0°C followed by methanesulfonamide (30.3 mg, 0.32 mmol, 1.1 equiv). After stirring for 5 min at 0°C, 2b (100 mg, 0.29 mmol) was added in one portion. The reaction mixture was stirred at 0°C for 24 h and then quenched with solid Na₂SO₃. The stirring was continued for an additional 45 min and the solution was extracted with EtOAc (5×10 mL). The combined organic phases were washed with KOH (2N), water, brine, then dried (Na₂SO₄) and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (4:1) as eluent to give 9b (52 mg, 47%) as a white solid. Further elution gave 9a (17 mg, 16%) as a colorless oil. Data for 9a: $[\alpha]_D^{25} = +18.7$ (c = 0.7, CHCl₃); IR (CHCl₃): $\tilde{\nu}_{max} = 3456$, 2950, 2931, 2859, 1790, 1689, 1599, 1472, 1409, 1264, 1210, 1162, 1126, 1087, 1030, 981, 947, 840, 779, 745, 692 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.97-7.95$ (m, 2H), 7.65–7.61 (m, 1H), 7.49 (t, J=7.8 Hz, 2H), 5.21-5.20 (m, 1H), 4.83-4.80 (m, 1H), 4.64 (dd, J=6.6, 4.2 Hz, 1 H), 4.49 (dd, J=6.6, 3.0 Hz, 1 H), 4.07 (br s, 1 H, OH), 2.80 (dd, J=17.5, 5.5 Hz, 1 H), 2.57 (dd, J=17.5, 2.0 Hz, 1 H), 1.71 (br s, 1H, OH), 0.96 (s, 9H), 0.20 (s, 3H), 0.19 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 198.6$, 174.2, 134.1, 133.7, 128.8, 128.6, 128.56, 84.5, 73.2, 71.6, 69.5, 39.7, 25.7, 25.3, 17.9, -4.3, -4.6 ppm; HRMS: m/z: calcd for [C₁₉H₂₈O₆Si+H]⁺: 381.1733; found: 381.1732. Data for 9b: m.p. 136–138 °C; $[\alpha]_{D}^{25} = -19.4$ (c = 0.6, CHCl₃); IR (CHCl₃): $\tilde{\nu}_{max} = 3368$, 2930, 2857, 1795, 1693, 1407, 1267, 1200, 1146, 1113, 1091, 1040, 983, 874, 839, 779 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.94-7.92$ (m, 2H), 7.65-7.61 (m, 1H), 7.51 (t, J=7.7 Hz, 2H), 5.37 (d, J=3.9 Hz, 1H), 4.58 (dd, J=4.2, 3.0 Hz, 1 H), 4.46-4.38 (m, 2 H), 4.11 (br s, 1 H, OH), 2.78 (dd, J=17.2, 4.7 Hz, 1 H), 2.50 (d, J=17.2 Hz, 1 H), 2.26 (br s, 1 H, OH), 0.67 (s, 9H), 0.04 (s, 3H), -0.10 ppm (s, 3H); ¹³C NMR (100 MHz,

CDCl₃): δ =199.6, 175.0, 134.2, 132.9, 129.0, 128.6, 82.5, 73.2, 68.6, 68.5, 39.9, 25.3, 17.7, -4.8, -5.7 ppm; HRMS: *m*/*z*: calcd for [C₁₉H₂₈O₆Si+H]⁺: 381.1733; found: 381.1726.

Dihydroxylation of 2b Under Upjohn Conditions^[17] to give 9a and 9b

NMO (16.9 mg, 0.144 mmol, 2.0 equiv) and $K_2OsO_4 \cdot 2H_2O$ (1.33 mg, 0.0036 mmol, 5 mol%) were added to a solution of **2b** (25 mg, 0.072 mmol) in acetone/water (4:1, 2 mL) at room temperature and stirred for 24 h. The mixture was then quenched with solid Na₂SO₃ and stirred for 1 h. Water was added and the solution was extracted with EtOAc (3×10 mL). The combined organic phases were washed with brine, dried (Na₂SO₄), and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (3:1) as eluent to afford a mixture of **9a** and **9b** (15.6 mg, 57%) as waxy solid. Analysis of this mixture by ¹H NMR spectroscopy indicated **9a**/**9b**=1:10.

(4R,5R)-4-(tert-Butyldimethylsilyloxy)-5-[(1S,2R,3R)-1,2,3-trihydroxy-3 phenylpropyl]dihydrofuran-2(3H)-one (**10a**)

Cerium chloride heptahydrate (30 mg, 0.079 mmol, 1.2 equiv) was added to a stirred solution of 9a (25 mg, 0.066 mmol) in methanol (2 mL) at room temperature and then cooled to -78°C. Sodium borohydride (3.0 mg, 0.079 mmol, 1.2 equiv) was added in one portion and stirred for 30 min. After warming to room temperature, the reaction was quenched with water (3 mL) and extracted with EtOAc (3×5 mL). The combined organic extracts were washed with brine, dried (Na2SO4) and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (1:1) as eluent to give 10a (22.6 mg, 90 %) as a white solid: m.p. 110–112 °C; $[\alpha]_{\rm D}^{25} = -12.4$ (c = 0.3, CHCl₃); IR (CHCl₃): $\tilde{\nu}_{max} = 3447$, 3019, 2930, 2857, 1778, 1464, 1258, 1216, 1164, 1097, 1027, 947, 915, 840, 806, 760, 702 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.40-7.30$ (m, 5H), 4.94 (d, J = 5.0 Hz, 1H), 4.56-4.50 (m, 1 H), 4.49 (t, J = 4.9 Hz, 1 H), 4.25 (dd, J = 5.2, 2.4 Hz, 1 H), 3.83 (d, J =3.2 Hz, 1H), 3.43 (br s, 1H, OH), 3.22 (br s, 1H, OH), 2.85 (br s, 1H, OH), 2.70 (dd, J=17.3, 5.8 Hz, 1 H), 2.53 (dd, J=17.3, 2.8 Hz, 1 H), 0.80 (s, 9H), 0.05 (s, 3H), 0.03 ppm (s, 3H); ${}^{13}C$ NMR (100 MHz, CDCl₃): $\delta \!=\! 174.6,\, 140.4,\, 128.7,\, 128.1,\, 126.3,\, 84.3,\, 75.9,\, 73.4,\, 69.3,\, 69.2,\, 39.2,\, 25.5,\,$ 17.7, -4.6, -5.0 ppm; HRMS: m/z: calcd for $[C_{19}H_{30}O_6Si+H]^+$: 383.1890; found: 383.1895.

(4R,5R)-4-(tert-Butyldimethylsilyloxy)-5-[(1R,2S,3S)-1,2,3-trihydroxy-3-phenylpropyl]dihydrofuran-2(3H)-one (**10b**)

The title compound was prepared from **9b** (55 mg, 0.145 mmol) by a similar procedure as described for **10a**, to give **10b** (50.3 mg, 91%) as a white solid: m.p. 114–115 °C; $[a]_D^{25} = +25.0$ (c=1.0, CHCl₃); IR (CHCl₃): $\tilde{v}_{max} = 3432$, 2930, 2858, 1775, 1411, 1255, 1208, 1161, 1092, 1039, 954, 906, 839, 779, 701 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.36-7.28$ (m, 5H), 5.05 (d, J=4.5 Hz, 1H), 4.53 (t, J=3.7 Hz, 1H), 4.36 (dd, J=9.3, 3.3 Hz, 1H), 4.13 (d, J=8.4 Hz, 1H), 3.96 (d, J=3.8 Hz, 1H), 3.14 (br s, 2H, OH), 2.97 (br s, 1H, OH), 2.64 (dd, J=17.3, 4.9 Hz, 1H), 2.36 (d, J=17.3 Hz, 1H), 0.80 (s, 9H), 0.06 (s, 3H), 0.05 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 175.7$, 140.0, 128.6, 127.8, 125.8, 81.9, 77.1, 72.7, 68.5, 66.7, 39.7, 25.5, 25.47, 17.8, -4.9, -5.3 ppm; HRMS: m/z: calcd for [C₁₉H₃₀O₆Si+H]⁺: 383.1890; found: 383.1893.

(4R,5S)-4-Hydroxy-5-[(1S,2R,3R)-1,2,3-trihydroxy-3-phenylpropyl]dihydrofuran-2(3H)-one, (+)-cardiobutanolide (1)

Amberlyst 15 resin (10 mg) was added to a stirred solution of **10a** (13 mg, 0.034 mmol) in anhydrous MeCN (2 mL) at 0 °C. The reaction was then warmed to room temperature and stirred for 12 h. The mixture was filtered through a small pad of celite and washed with EtOAc (30 mL). The filtrate was concentrated to give virtually pure **1** (9.1 mg, quant) as a colorless solid: m.p. 190–191 °C; $[a]_D^{25} = +7.6$ (c=0.2, MeOH), lit.^[1] m.p. 189–190 °C, $[a]_D^{24} = +6.4$ (c=0.28, MeOH); IR (KBr): $\tilde{\nu}_{max} = 3517$, 3478, 3377, 2925, 2853, 1759, 1638, 1455, 1373, 1275, 1209, 1169, 1106, 1078, 1056, 1028, 1012, 986, 917, 858, 790, 774, 774, 702 cm⁻¹; ¹H NMR (400 MHz, [D₆]acetone): $\delta = 7.45$ (d, J = 7.0 Hz, 2H), 7.30 (t, J = 7.3 Hz, 2H), 7.22 (t, J = 7.3 Hz, 1H), 4.79 (d, J = 7.2 Hz, 1H), 4.60 (t,

J=4.1 Hz, 1 H), 4.56 (dd, J=7.8, 3.5 Hz, 1 H), 4.39 (d, J=7.7 Hz, 1 H), 3.90 (d, J=6.9 Hz, 1 H), 2.85 (dd, J=17.2, 5.2 Hz, 1 H), 2.37 ppm (dd, J=17.2, 0.9 Hz, 1 H); ¹³C NMR (100 MHz, [D₆]acetone); δ =176.3, 144.2, 128.6, 127.9, 127.8, 86.7, 75.3, 74.0, 70.1, 68.5, 40.4 ppm; HRMS: m/z: calcd for [C₁₃H₁₆O₆+Na]⁺: 291.0845; found: 291.0851.

(4R,5S)-4-Hydroxy-5-[(1R,2S,3S)-1,2,3-trihydroxy-3-phenylpropyl]dihydrofuran-2(3H)-one (11)

The title compound was prepared from **10b** (50 mg, 0.13 mmol) by a similar procedure as described for **1**, to give **11** (35 mg, quant) as a white solid: m.p. 155–156 °C; $[a]_D^{25} = +47.4$ (c=0.5, MeOH); IR (KBr): $\bar{v}_{max} = 3427$, 2925, 2854, 1757, 1605, 1443, 1336, 1295, 1233, 1171, 1109, 1011, 906, 768, 705 cm⁻¹; ¹H NMR (400 MHz, [D₆]acetone): $\delta = 7.44$ (d, J = 7.2 Hz, 2H), 7.32 (t, J = 7.4 Hz, 2H), 7.24–7.21 (m, 1H), 4.80 (d, J = 7.6 Hz, 1H), 4.79 (s, 1H, OH), 4.64 (dd, J = 4.8, 3.4 Hz, 1H), 4.51 (br s, 1H, OH), 4.47 (dd, J = 9.4, 3.2 Hz, 1H), 4.41–4.37 (m, 1H), 4.20 (br s, 1H, OH), 3.74 (d, J = 7.3 Hz, 1H), 2.88 (dd, J = 17.3, 5.2 Hz, 1H), 2.35 ppm (d, J = 17.3 Hz, 1H); ¹³C NMR (100 MHz, [D₆]acetone): $\delta = 176.3$, 144.3, 128.7, 127.8, 82.7, 75.2, 74.6, 68.6, 67.7, 39.6 ppm; HRMS: m/z: calcd for [C₁₃H₁₆O₆+Na]⁺: 291.0845; found: 291.0834.

Sharpless Asymmetric Dihydroxylation of 5b to afford 9a and 9b

K₂OsO₄·2H₂O (0.126 mg, 0.000344 mmol, 0.4 mol %) was added to a mixture of K₃Fe(CN)₆ (85.6 mg, 0.26 mmol, 3.0 equiv), K₂CO₃ (35.9 mg, 0.26 mmol, 3.0 equiv) and (DHQD)₂PHAL (0.67 mg, 0.00086 mmol, 1 mol %) in *t*BuOH/H₂O (1:1, 2 mL), cooled at 0 °C followed by methanesulfonamide (8.2 mg, 0.086 mmol, 1.0 equiv). After stirring for 5 min at 0 °C, **5b** (30 mg, 0.086 mmol) was added in one portion. The reaction mixture was stirred at 0 °C for 12 h and then quenched with solid Na₂SO₃. The stirring was continued for an additional 45 min and the solution extracted with EtOAc (5×10 mL). The combined organic phases were washed with KOH (2 N), water and brine, then dried (Na₂SO₄) and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (4:1) as eluent to give **9b** (21.3 mg, 65 %) as a colorless solid. Further elution gave **9a** (6.9 mg, 21%) as a colorless oil. **9a**: $[a]_{D}^{25} = +18.4$ (*c*=0.2, CHCl₃); **9b**: $[a]_{D}^{25} =$ -19.0 (*c*=0.4, CHCl₃).

Dihydroxylation of **5b** under Upjohn Conditions^[17] to give **9a** and **9b**

NMO (20.2 mg, 0.172 mmol, 2.0 equiv) and K_2OsO_4 ·2H₂O (1.6 mg, 0.0043 mmol, 5 mol%) were added to a solution of **5b** (30 mg, 0.086 mmol) in acetone/water (4:1, 1.2 mL) at room temperature and stirred for 12 h. The mixture was then quenched with solid Na₂SO₃ and stirred for 1 h. Water was added and the solution extracted with EtOAc (3×10 mL). The combined organic phases were washed with brine, dried (Na₂SO₄) and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (3:1) as eluent to afford a mixture of **9a** and **9b** (16.7 mg, 51%) as a waxy solid. Analysis of this mixture by ¹H NMR spectroscopy indicated **9a/9b** = 1:7.

Sharpless Dihydroxylation of (\pm) -6a

K₂OsO₄·2H₂O (1.1 mg, 0.003 mmol, 0.4 mol%) was added to a mixture of K₃Fe(CN)₆ (736 mg, 2.235 mmol, 3.0 equiv), K₂CO₃ (309 mg, 2.235 mmol, 3.0 equiv) and (DHQD)₂PHAL (5.8 mg, 0.00745 mmol, 1 mol%) in tBuOH-H₂O (1:1, 8 mL) cooled at 0°C followed by methanesulfonamide (71 mg, 0.745 mmol, 1.0 equiv). After stirring for 5 min at 0°C, (±)-6a (100 mg, 0.745 mmol) was added in one portion. The reaction mixture was stirred at 0°C for 12 h and then quenched with solid Na₂SO₃. The stirring was continued for an additional 45 min and the solution extracted with EtOAc (5×10 mL). The combined organic phases were washed with KOH (2N), water, and brine, then dried (Na₂SO₄) and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (1:1) as eluent to give $(-)-12^{[21]}$ (46 mg, 37%) as a colorless solid and further elution provided $13^{[22]}$ (45 mg, 36%) as a colorless oil. Data for (-)-12:^[21] Mp 80-82 °C; $[a]_{D}^{25} =$ -33.6 (c = 0.4, CH₂Cl₂) lit.^[21] for (R)-enantiomer, $[a]_D^{23} = +72.1$ (c = 8.0, CH₂Cl₂); IR (CHCl₃): ṽ_{max}=3447, 3066, 2928, 2884, 1686, 1597, 1580,

ASIAN JOURNAL

OF ORGANIC CHEMISTRY

1450, 1401, 1319, 1264, 1229, 1182, 1118, 1603, 1002, 978, 962, 885, 847, 691 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =7.95 (d, *J*=7.3 Hz, 2H), 7.64 (t, *J*=7.4 Hz, 1H), 7.54 (t, *J*=7.7 Hz, 2H), 5.21–5.15 (m, 1H), 4.04 (s, 1H, OH), 4.02 (d, *J*=10.2 Hz, 1H), 3.77 (dd, *J*=11.6, 4.2 Hz, 1H), 2.22 ppm (br s, 1H, OH); ¹³C NMR (100 MHz, CDCl₃): δ =199.4, 134.3, 133.4, 129.0, 128.5, 74.6, 65.3 ppm. Data for **13**^{:[22]} IR (CHCl₃): $\tilde{\nu}_{max}$ = 3401, 1647, 1456, 1316, 1217, 1154, 1106, 1031, 769 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): mixture of diastereomers (ca. 1:1), δ =7.30–7.25 (m, 10H), 4.78 (d, *J*=4.1 Hz, 1H), 4.58 (d, *J*=6.9 Hz, 1H), 4.18 (br s, 1H, OH), 3.95 (br s, 2H, OH), 3.74 (br d, 3H), 3.64–3.60 (m, 3H), 3.56–3.36 ppm (m, 3H); ¹³C NMR (100 MHz, CDCl₃): mixture of diastereomers (ca. 1:1), δ =140.5, 140.4, 128.4, 128.3, 128.0, 127.6, 126.7, 126.3, 76.0, 75.2, 74.9, 74.6, 63.0, 62.5 ppm.

(4R,5R)-4-(tert-Butyldimethylsilyloxy)-5-[(1S,2S,3R)-3-(tertbutyldimethylsilyloxy)-1,2-dihydroxy-3-phenylpropyl]dihydrofuran-2(3H)-one (**14 a**) and (4R,5R)-4-(tert-butyldimethylsilyloxy)-5-[(1R,2R,3R)-3-(tert-butyldimethylsilyloxy)-1,2-dihydroxy-3phenylpropyl]dihydrofuran-2(3H)-one (**14 b**)

K₂OsO₄.2H₂O (0.55 mg, 0.0015 mmol, 1.0 mol%) was added to a mixture of $K_3Fe(CN)_6$ (300 mg, 0.907 mmol, 6.0 equiv), K_2CO_3 (126 mg, 0.907 mmol, 6.0 equiv) and (DHQD)₂PHAL (4.7 mg, 0.006 mmol, 4.0 mol%) in tBuOH/H2O (1:1, 2 mL) cooled at 0°C, followed by methanesulfonamide (14 mg, 0.15 mmol, 1.0 equiv). After stirring for 5 min at 0°C, the solution of 5d (70 mg, 0.15 mmol) in tBuOH (1 mL) was added in one portion. The reaction mixture was stirred at 0°C for 48 h and then quenched with solid Na2SO3. The stirring was continued for an additional 45 min and the solution extracted with EtOAc (5×10 mL). The combined organic phases were washed with KOH (2n), water, and brine, then dried (Na₂SO₄) and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (5:1) as eluent to give 14b (28 mg, 37%) as colorless oil. Further elution with petroleum ether/EtOAc (4:1) gave 14c (5.2 mg, 7%) as colorless oil. Elution then with petroleum ether/EtOAc (7:3) gave 14a (23.3 g, 31%) as a colorless oil. Data for **14a**: $[a]_{D}^{25} = -40.5$ (c = 0.4, CHCl₃); IR (CHCl₃): $\tilde{\nu}_{max} = 3461$, 3020, 2957, 2931, 2859, 1779, 1472, 1405, 1388, 1362, 1258, 1216, 1163, 1097, 1061, 1023, 948, 860, 839, 806, 701 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.40-7.27$ (m, 5 H), 4.85 (d, J = 6.6 Hz, 1H), 4.57-4.50 (m, 1H), 4.47-4.45 (m, 1H), 4.41 (dd, J=5.8, 1.6 Hz, 1H), 3.72–3.67 (m, 1H), 3.06 (br s, 1H, OH), 2.67 (dd, J=17.2, 5.8 Hz, 1H), 2.56 (dd, J=17.2, 3.3 Hz, 1H), 2.27 (br s, 1H, OH), 0.85 (s, 9H), 0.84 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H), -0.16 ppm (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 174.6$, 141.3, 128.5, 128.0, 127.0, 85.5, 76.6, 74.9, 69.0, 67.8, 39.2, 25.8, 25.7, 18.1, 17.8, -4.6, -4.8, -4.81, -5.1 ppm; HRMS: m/z: calcd for $[C_{25}H_{44}O_6Si_2+Na]^+$: 519.2574; found: 519.2570. Data for **14b**: $[\alpha]_D^{25} = -28.0$ (c = 0.5, CHCl₃); IR (CHCl₃): $\bar{v}_{\rm max}\!=\!3480,\;3022,\;2955,\;2931,\;2859,\;1790,\;1472,\;1363,\;1258,\;1162,\;1090,\\1036,\;953,\;839,\;809,\;702\;{\rm cm}^{-1};\;^1{\rm H}\,{\rm NMR}\;(400\;{\rm MHz},\;{\rm CDCl}_3):\;\delta\!=\!7.34\!-\!7.28$ (m, 5H), 4.79 (d, J=7.9 Hz, 1H), 4.56–4.54 (m, 1H), 4.33 (dd, J=9.3, 3.3 Hz, 1H), 3.84 (d, J=7.8 Hz, 1H), 3.68 (t, J=8.8 Hz, 1H), 3.00 (s, 1 H, OH), 2.65 (dd, J=17.2, 4.8 Hz, 1 H), 2.38 (d, J=17.2 Hz, 1 H), 2.36 (s, 1H, OH), 0.89 (s, 9H), 0.78 (s, 9H), 0.05 (s, 3H), 0.04 (s, 6H), -0.22 ppm (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 175.1$, 140.1, 128.4, 128.1, 127.1, 82.4, 76.4, 75.0, 68.6, 65.8, 39.8, 25.7, 25.5, 18.0, 17.8, -4.5, -4.9, -5.2 -5.4 ppm; HRMS: m/z: calcd for $[C_{25}H_{44}O_6Si_2+Na]^+$ 519.2574; found: 519.2568. Data for **14c**: $[\alpha]_{D}^{25} = -3.6$ (c = 0.5, CHCl₃); IR (CHCl₃): $\tilde{\nu}_{max} = 3436$, 3019, 2930, 2957, 1788, 1650, 1464, 1260, 1100, 1048, 839, 702 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): $\delta = 7.39-7.29$ (m, 5H), 5.44 (d, J = 2.3 Hz, 1H), 5.23 (d, J = 2.9 Hz, 1H), 5.07 (t, J = 4.1 Hz, 1H), 4.80 (d, J=3.9 Hz, 1H), 4.28 (s, 1H), 3.89 (t, J=2.8 Hz, 1H), 2.75 (dd, J = 18.6, 5.3 Hz, 2H), 0.89 (s, 18H), 0.12 (s, 6H), -0.01 (s, 3H), -0.03 ppm (s, 3 H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 175.5$, 139.4, 128.7, 128.2, 125.9, 87.6, 82.5, 77.2, 75.9, 74.2, 36.2, 25.5, 18.1, -5.1, -5.4 ppm; HRMS: m/z: calcd for $[C_{25}H_{44}O_6Si_2+Na]^+$: 519.2574; found: 519.2565.

(4R,5S)-4-Hydroxy-5-[(1R,2S,3R)-1,2,3-trihydroxy-3-phenylpropyl]dihydrofuran-2(3H)-one (15)

The title compound was prepared from **14b** (45 mg, 0.0906 mmol) by a similar procedure as described for **1** to give **15** (24.2 mg, quant) as

white solid: m.p. 168–170 °C; $[\alpha]_D^{25} = +5.4$ (c=0.5, MeOH); IR (KBr): $\tilde{\nu}_{max} = 3452$, 3022, 2926, 2854, 1773, 1652, 1458, 1262, 1122, 1028, 908 cm⁻¹; ¹H NMR (400 MHz, [D₆]acetone): $\delta = 7.44$ (d, J=7.1 Hz, 2H), 7.32 (t, J=7.4 Hz, 2H), 7.25 (t, J=7.3 Hz, 1H), 4.87 (d, J=7.2 Hz, 1H), 4.62 (d, J=4.0 Hz, 1H), 4.58 (br s, 1H, OH), 4.48 (dd, J=9.0, 3.4 Hz, 1H), 4.32 (br s, 1H, OH), 4.04 (br s, 2H, OH), 3.79–3.72 (m, 2H), 2.88–2.84 (m, overlapped by residual water, 1H), 2.30 ppm (d, J=17.3 Hz, 1H); ¹³C NMR (100 MHz, [D₆]acetone): $\delta = 176.0$, 142.9, 128.9, 128.2, 127.9, 82.7, 75.72, 75.7, 68.6, 68.5, 39.6 ppm; HRMS: m/z: calcd for [C₁₃H₁₆O₆+Na]⁺: 291.0845; found: 291.0852.

Synthesis of 1 by Dihydroxylation of 5 a

NMO (30 mg, 0.256 mmol, 2.0 equiv) and K₂OsO₄·2H₂O (2.36 mg, 0.0064 mmol, 5 mol%) were added to a solution of olefin **5a** (30 mg, 0.128 mmol) in acetone/water (4:1, 2 mL) at 0°C. The reaction mixture was stirred at room temperature for 14 h. The mixture was then quenched with solid Na₂SO₃ and stirred for 1 h. Water was added and the solution extracted with EtOAc (3×10 mL). The combined organic phases were washed with brine, dried (Na₂SO₄), and concentrated. The residue was purified by chromatography on a silica gel column with petroleum ether/EtOAc (1:4) as eluent to give (+)-cardiobutanolide 1 (21 mg, 61%) as a white solid: m.p. 190–191 °C; $[a]_D^{25} = +7.7$ (*c*=0.5, MeOH). Further elution gave the diastercomer **15** (5.1 mg, 15%) as white solid: m.p. 168–170 °C; $[a]_D^{25} = +5.6$ (*c*=0.3, MeOH).

Acknowledgements

This work was financially sponsored by the Industrial Research and Consultancy Centre (IRCC), Indian Institute of Technology Bombay. P.K. thanks the Council of Scientific and Industrial Research (CSIR), New Delhi for a research fellowship.

- A. Hisham, M. Toubi, W. Shuaily, M. D. A. Bai, Y. Fijimoto, *Phytochemistry* 2003, 62, 597.
- [2] a) F. R. Chang, J. L. Wei, C. M. Teng, Y. C. Wu, J. Nat. Prod. 1998, 61, 1457; b) H. Yang, X. Li, Y. Tang, N. Zhang, J. Chen, B. Cai, J. Pharm. Biomed. Anal. 2009, 49, 140.
- [3] a) E. Pérez, J. Sáez, S. Blair, X. Franck, B. Figadère, Lett. Org. Chem. 2004, 1, 102; b) C. A. Carollo, A. R. Hellmann-Carollo, J. M. Siqueira, S. Albuquerque, J. Chil. Chem. Soc. 2006, 51, 837; c) D. B. Silva, M. F. C. Matos, S. T. Nakashita, C. K. Misu, N. C. Yoshida, C. A. Carollo, J. R. Fabri, H. S. Miglio, J. M. Siqueira, Quim. Nova 2007, 30, 1809; d) S. Puvanendran, T. Manoranjan, A. Wickramasinghe, D. N. Karunaratne, V. Kumar, S. Wijesundara, G. Carr, R. Andersen, V. Karunaratne, J. Natl. Sci. Found. Sri Lanka 2010, 38, 75.
- [4] I. C. Moreira, J. H. G. Lago, N. F. Roque, *Biochem. Syst. Ecol.* 2005, 33, 948.
- [5] a) M. A. Blázquez, A. Bermejo, M. C. Zafra-Polo, D. Cortes, *Phytochem. Anal.* 1999, 10, 161; b) H. B. Mereyala, M. Joe, *Curr. Med. Chem. Anti-Cancer Agents* 2001, 1, 293.
- [6] a) P. Ruiz, J. Murga, M. Carda, J. A. Marco, J. Org. Chem. 2005, 70, 713; b) D. Matsuura, K. Takabe, H. Yoda, Tetrahedron Lett. 2006, 47, 1371; c) P. Radha Krishna, P. V. N. Reddy, Tetrahedron Lett. 2006, 47, 4627; d) A. Garg, R. P. Singh, V. K. Singh, Tetrahedron 2006, 62, 11240; e) K. R. Prasad, S. L. Gholap, J. Org. Chem. 2008, 73, 2916; f) P. Radha Krishna, E. S. Kumar, Tetrahedron Lett. 2009, 50, 6676; g) J. S. Yadav, B. Madhavarao, K. S. Rao, Synlett 2009, 3179; h) S. Chandrasekhar, N. Kiranmai, Tetrahedron Lett. 2010, 51, 4058; i) P. Pal, A. K. Shaw, Tetrahedron 2011, 67, 4036.
- [7] a) R. W. Hoffmann, *Synthesis* 2006, 3531; b) I. S. Young, P. S. Baran, *Nat. Chem.* 2009, *1*, 193.
- [8] a) R. A. Fernandes, A. K. Chowdhury, J. Org. Chem. 2009, 74, 8826; b) R. A. Fernandes, A. B. Ingle, Synlett 2010, 158; c) R. A. Fernandes, S. V. Mulay, J. Org. Chem. 2010, 75, 7029; d) R. A. Fernandes, S. V. Mulay, Synlett 2010, 2667; e) R. A. Fernandes, A. B.

Ingle, *Tetrahedron Lett.* 2011, 52, 458; f) R. A. Fernandes, A. K. Chowdhury, *Eur. J. Org. Chem.* 2011, 1106; g) R. A. Fernandes, P. Kattanguru, *Tetrahedron: Asymmetry* 2011, 22, 1930.

- [9] J. Song, R. I. Hollingsworth, Tetrahedron: Asymmetry 2001, 12, 387.
- [10] O. Andrey, J. Sperry, U.S. Larsen, M.A. Brimble, *Tetrahedron* 2008, 64, 3912.
- [11] For selected references on cross-metathesis, see: a) A. K. Chatterjee, T. L. Choi, D. P. Sanders, R. H. Grubbs, J. Am. Chem. Soc. 2003, 125, 11360; b) A. H. Hoveyda, P. J. Lombardi, R. V. O'Brien, A. R. Zhugralin, J. Am. Chem. Soc. 2009, 131, 8378; c) K. Voigtritter, S. Ghorai, B. H. Lipshutz, J. Org. Chem. 2011, 76, 4697 and references therein.
- [12] a) S. B. Garber, J. S. Kingsbury, B. L. Gray, A. H. Hoveyda, J. Am. Chem. Soc. 2000, 122, 8168; b) S. Gessler, S. Randl, S. Blechert, Tetrahedron Lett. 2000, 41, 9973.
- [13] The reaction of 3a with 6a with the G-II catalyst is known in the literature to give 5a.^[61] However, the product could not be separated from the catalyst. After repetition of this reaction several times, we only obtained dimerization of 6a.
- [14] For reviews, see: a) H. C. Kolb, M. S. Van Nieuwenhze, K. B. Sharpless, *Chem. Rev.* **1994**, *94*, 2483; b) C. Bolm, J. P. Hildebrand, K. Muniz in *Catalytic Asymmetric Synthesis*, *2nd ed.* (Ed.: I. Ojima), Wiley-VCH, New York, **2000**, pp. 399; c) A. B. Zaitsev, H. Adolfsson, *Synthesis* **2006**, 1725.

- [15] For CBS reduction, see: a) E. J. Corey, E. C. J. Helal, Angew. Chem. 1998, 110, 2092; Angew. Chem. Int. Ed. 1998, 37, 1986; b) J. Garcia, M. López, J. Romeu, Tetrahedron: Asymmetry 1999, 10, 2617.
- [16] The diastereomeric ratio was determined by ¹H NMR spectroscopy. Assignment of the stereocenters was based on conversion of 9a into the final compound 1.
- [17] For dihydroxylation with NMO, see: a) V. Vanrheenen, R. C. Kelly,
 D. Y. Cha, *Tetrahedron Lett.* **1976**, *17*, 1973; b) L. Ahrgren, L.
 Sutin, *Org. Process Res. Dev.* **1997**, *1*, 425; c) J. A. Gladding, J. P.
 Bacci, S. A. Shaw, A. B. Smith, III, *Tetrahedron* **2011**, *67*, 6697.
- [18] For matched or mismatched stereoselectivity in double diastereoselection in asymmetric dihydroxylation of chiral olefin substrates, see ref. 14a.
- [19] For a similar highly diastereoselective reduction, see ref. 6d.
- [20] The SAD reaction of 5b is known in the literature to give nonisolable products.^[6f] Reaction details were not available.
- [21] M. A. Delton, G. U. Yuen, J. Org. Chem. 1968, 33, 2473.
- [22] Z. Wang, Y. T. Cui, Z. B. Xu, J. Qu, J. Org. Chem. 2008, 73, 2270.
- [23] A provisional process patent on this work has been filed, application no. 1780/MUM/2012.

Received: October 3, 2012 Revised: October 16, 2012 Published online: November 13, 2012